Clinical Trial Update: Multiple Ascending Dose Study of SPC5001 in Treatment of Healthy Subjects and Subjects With FH [Phase 1]

View source ↗

Summary

A Phase 1 multiple ascending-dose study of SPC5001 in healthy subjects and individuals with familial hypercholesterolemia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Familial Hypercholesterolemia
• Hypercholesterolemia

Drugs mentioned

• SPC5001

Snippet

Sponsor: Santaris Pharma A/S | Conditions: Hypercholesterolemia | Phase 1 | Status: TERMINATED